INTRODUCTION
============

Cancer is a disease in which constant clonal expansion of somatic cells kill by invading, subverting and eroding normal tissues ([@b1-tr-35-271]). The treatment methods to fight against cancer comprise chemotherapy, radiotherapy, hormone therapy, and surgery ([@b2-tr-35-271]); however, each of them has its own disadvantages and severely affects patient's normal cell. Therefore, the use of natural products nowadays has been contemplated of outstanding value in controlling cancer. Plant extracts can cause apoptosis through induction of caspase pathway ([@b3-tr-35-271]). Apoptosis is a programmed cell death and a highly arranged manner to eradicate cancerous cells and plays a key role in tissue homeostasis and maintenance ([@b4-tr-35-271]). Proteolytic enzymes such as caspases are central effector molecules in apoptosis and their activation or inactivation is vital in controlling cancer ([@b5-tr-35-271]).

*Citrus macroptera*, also known as "wild orange" ([@b6-tr-35-271]), is an indigenous fruit of Malaysia, Melanesia ([@b7-tr-35-271]) and Bangladesh ([@b8-tr-35-271]). *C. macroptera* is available in the hilly areas of north-eastern Bangladesh (Sylhet Division). Locally it is known as "Satkara" and has long been used to treat hypertension, stomach pain, alimentary disorders ([@b9-tr-35-271]) and fever ([@b10-tr-35-271]). *C. macroptera* fruit is significantly cytotoxic ([@b11-tr-35-271]). The fruit pulp was reported to contain 2.89 ± 0.32 mg proteins and antioxidants including 291.06 ± 10.14 mg polyphenols, 145.02 ± 0.36 mg flavonoids, 526.08 ± 3.32 mg tannin, and 120.83 ± 0.0019 mg ascorbic acids per 100 g dry weight and significant radical scavenging activity was confirmed by an *in vitro* study ([@b12-tr-35-271]). Epidemiological studies showed that many of these antioxidants possess anti-inflammatory, anti-atherosclerotic, anti-cancer, anti-mutagenic, anti-carcinogenic, anti-bacterial, and anti-viral activities ([@b13-tr-35-271]). Considering the information mentioned above, this current study was undertaken to investigate the anti-proliferative activity of *C. macroptera* fruit pulp juice (CMFPJ) against Ehrlich's ascites carcinoma (EAC) in mice.

MATERIALS AND METHODS
=====================

Chemicals and reagents
----------------------

Dulbecco's modified Eagle's medium (DMEM) and 3-\[4, 5-dimethylthiazol-2-yl\]-2, 5- diphenyltetrazolium bromide (MTT) were bought from Sigma-Aldrich (St. Louis, MO, USA). Hemagglutination buffer was prepared as 20 mM Tris-HCl buffer, pH 7.8 containing 1% NaCl and 10 mM CaCl~2~. Trypan blue was bought from Invitrogen (Carlsbad, CA, USA). M-MLV (Moloney Murine Leukemia Virus) reverse-transcriptase was purchased from Tiangen (Beijing, China), primers were custom synthesized from IDT (Integrated DNA Technologies), Seri Kembangan, Selangor, Malaysia. GoTaq^®^ qPCR Master Mix (2X) was collected from Promega (Madison, WI, USA). All other chemicals and reagents used were of analytical grade.

Plant sample
------------

The fruits of *C. macroptera* were collected in mid-October, 2015 from a local market of Sylhet, Bangladesh. The collected fruits were authenticated by a taxonomist of the Department of Botany, University of Rajshahi (Rajshahi, Bangladesh); where a voucher specimen has been preserved under accession number 00212 for future reference.

Preparation of C. macroptera fruit pulp juice
---------------------------------------------

The thick rind of *C. macroptera* fruit was removed by using a sharp knife with gloved hand to collect pulp. The pulp was cut into small pieces and juice was collected by squeezing the pieces of pulp with gloved hand. The juice was dried with VirTis BenchTop Pro Freeze Dryer (SP Scientific, Stone Ridge, NY, USA) and dissolved in distilled water at 1 g/10 mL concentration. Juice was filtered by using Glass Fiber Filter paper (Macherey NAGEL GmBH, Düren, Germany) with DURAN^®^ Filtering Apparatus (Mainz, Germany) at room temperature. Finally, the juice filtrate was again dried with VirTis BenchTop Pro Freeze Dryer and stored at −20°C for further use.

Experimental animal and EAC cell
--------------------------------

Male Swiss albino mice (25--30 g) were bought from the Department of Pharmacy of Jahangirnagar University (Dhaka, Bangladesh). The mice were housed in polypropylene cage (Tarson, Bangalore, India) and kept in the animal house of Institute of Biological Sciences (IBSc), University of Rajshahi under standard condition (12 hr light/dark cycle, 25 ± 2°C temperature and \~70% humidity). The animals were allowed to acclimatize for 1 week before beginning the experiment. Food and water were supplied *ad libitum*. Methodologies followed in this research work along with handling of experimental animal were approved by the Institutional Animal, Medical Ethics, Biosafety and Biosecurity Committee (IAMEBBC) for Experimentations on Animal, Human, Microbes and Living Natural Sources (license no: 31/320-IAMEBBC/IBSc), Institute of Biological Sciences (IBSc), University of Rajshahi. EAC cells used in this study were kindly provided by the Department of Pharmacy of Jahangirnagar University.

In vitro cytotoxicity test
--------------------------

*In vitro* cytotoxicity of CMFPJ was performed as described previously with a few modifications ([@b14-tr-35-271]). Cytotoxicity of CMFPJ on the growth of EAC cell was determined by measuring the metabolic capacity using the 3-\[4, 5-dimethylthiazol-2-yl\]-2, 5- diphenyltetrazolium bromide (MTT) assay. The MTT assay was carried out as follows: EAC cells (100 μL cells from 1 × 10^6^ cells/mL) were treated for 24 hr with five different doses of CMFPJ (500, 250, 125, 62.5, and 31.25 μg/mL in DMEM medium). After incubation at 37°C for 24 hr, 0.1 mg (50 μL of a 2 mg/mL solution) MTT was added to each well and the cells were again incubated at 37°C for 8 hr. The aliquot was carefully removed and 100 μL dimethylsulfoxide (DMSO) was then added to each well to dissolve the formazan crystal. The plate was read immediately at 540 nm on a multi-well plate reader (Multiskan™ FC Microplate Photometer, Thermo Scientific, Waltham, MA, USA). All the experiments were performed in triplicate and the mean absorbance values were calculated. The results were articulated as the percentage of inhibition by comparing to the untreated control. The following equation was used to calculate the cell proliferation inhibition percentage:
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where A is the OD~540\ nm~ of the cellular homogenate without CMFPJ (control) and B is the OD~540\ nm~ of the cellular homogenate with CMFPJ.

Hemagglutination assay
----------------------

To check the presence of lectin protein in CMFPJ, hemagglutination assay was performed with minor modification as described previously ([@b15-tr-35-271]). A final volume of 100 μL was prepared in 96-well flat-bottomed microtiter plate containing 50 μL of CMFJ (100 mg/mL) serially diluted with 50 μL hemagglutination buffer (20 mM Tris-HCl buffer, pH 7.8 containing 1% NaCl and 10 mM CaCl~2~) and 50 μL of 2% red blood cells (RBCs) suspension previously washed with 1% NaCl. PBS was used as a control. After a gentle shaking, the plate was set aside at room temperature for 30 min. The visual agglutination titer of the maximum dilution giving the positive agglutination was noted.

EAC inoculation and treatment procedure
---------------------------------------

EAC cells (200 μL) adjusted 10^6^ cells/mL in saline water (0.9% NaCl) were pre-inoculated into the *i.p*. of mice on the 1st day ([@b16-tr-35-271]). The mice were divided randomly into four groups (n = 6). CMFPJ at 25, 50, and 100 mg/kg/day dosage was administrated to the treatment groups in a total volume of 200 μL with distilled water for 7 consecutive days at a regular interval of 24 hr starting from 24 hr of post inoculation of EAC cells ([@b17-tr-35-271]). Control mice received 200 μL of saline solution each day.

In vivo cell growth inhibition assay. Cell growth
-------------------------------------------------

inhibition assay was carried out as described previously ([@b16-tr-35-271],[@b18-tr-35-271]). After 7 consecutive days of treatment, 5 mL saline water (0.9% NaCl) was injected into the peritoneum of mice of both control and treated groups and then they were anesthetized using chloroform. Then cells from peritoneum were harvested and diluted 10 times (100 μL: 900 μL) in saline. Thereafter, diluted cells were stained with Trypan blue dye for quantification of viable cells. Then 10 μL cell suspension was placed on hemocytometer and viable cells were counted by using Optika inverted microscope (Italy). Cell growth inhibition percentage was calculated by the following formula:
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where, T = mean number of EAC cells of CMFPJ treated group and C = mean number of EAC cells of control.

RNA isolation, reverse transcription and real time-PCR
------------------------------------------------------

Total RNA from EAC of control and CMFPJ treated mice were isolated after 24 hr of last treatment. RNA was extracted using RNAsimple Total RNA Kit (Tiangen, Beijing, China) according to the manufacturer's protocol. RNA quality was checked on 1% agarose gel stained with 10 μg/mL ethidium bromide and visualized via a gel documentation system (Alphaimager mini, New Taipei City, Taiwan). Concentration and purity of isolated RNA were measured by spectrometry at 260 and 280 nm. Isolated RNA was then converted to cDNA using TIANscript M-MLV reverse-transcriptase. For each reaction (20 μL), 1 μL of 10 mM oligo (dT), 1 μL dNTPs (10 mM), 1 μg RNA and nuclease-free water up to 15 μL were taken in PCR tube and incubated at 70°C for 5 min. The mixture was immediately chilled on ice for 3 min. 1 μL M-MLV reverse transcriptase, 4 μL (5X) of 1st strand buffer was added to each tube and incubated at 45°C for 50 min. Further, the mixture was incubated at 95°C for 5 min to inactivate the M-MLV reverse-transcriptase enzyme. Prepared cDNA was stored at −20°C for further use. The reverse transcription products were used as templates for real-time PCR. PCR amplification was performed using specific primers ([Table 1](#t1-tr-35-271){ref-type="table"}). Each reaction was performed in triplicate in 10 μL volume containing 5 μL GoTaq^®^ qPCR Master Mix (2X) (Promega, Madison, WI, USA), 0.5 μL (10 mM) of each primer, 3 μL nuclease free water and 1 μL template. Thermal cycling was performed for each gene on cDNA samples in 48-well reaction plates by using the Eco™ Real- Time PCR System (Illumina^®^, San Diego, CA, USA). Realtime PCR was conducted with the following cycling conditions: 95°C for 10 min, followed by 40 cycles of 95°C for 30 sec, 50°C for 30 sec and 72°C for 25 sec. PCR reaction specificity was confirmed by melt curve analysis at 95°C for 15 sec, 60°C for 15 sec, 95°C for 15 sec. The quantitation of gene expression was carried out using GAPDH as an endogenous control and relative to the calibrator sample using the ΔΔCq method.

Statistical analysis
--------------------

Data presented as mean ± SD (Standard Deviation) and graphs were prepared by using Microsoft Excel 2007 (Microsoft Corporation, Redmond, WA, USA). Analysis of variance (ANOVA) was performed using SPSS (IBM, version 16; SPSS Inc., Chicago, IL,

RESULTS
=======

In vitro cytotoxicity test
--------------------------

The *in vitro* cytotoxic effect of CMFPJ on EAC cells was in a dose-dependent manner ([Fig. 1](#f1-tr-35-271){ref-type="fig"}). The CMFPJ inhibited 87.3% EAC cells at 500 μg/mL concentration. The cytotoxic effect was in decreasing trend with the reduction of CMFPJ concentration and it reached to 13.9% at 31.25 μg/mL.

Hemagglutination assay
----------------------

Result regarding the hemagglutination assay demonstrated that CMFPJ has considerable agglutination activity on mouse RBCs ([Fig. 2](#f2-tr-35-271){ref-type="fig"}). CMFPJ showed hemagglutination activity on mouse RBCs at the very last concentration of 39.06 μg/100 μL. Thereafter, the presence of lectin in CMFPJ was confirmed from the well-established agglutination activity on mouse RBCs.

In vivo cell growth inhibition assay
------------------------------------

Result regarding cell growth inhibition revealed that CMFPJ significantly slowed down EAC growth *in vivo* in a dose-dependent manner ([Fig. 3](#f3-tr-35-271){ref-type="fig"}). The number of EAC counted in the control group were 5.53 × 10^6^ cells/mL, whereas 4.45 × 10^6^, 2.81 × 10^6^, and 1.72 × 10^6^ cells/mL were observed in the 25, 50, and 100 mg/kg CMFPJ treated group respectively ([Fig. 3](#f3-tr-35-271){ref-type="fig"}). According to the number of EAC cells, we found that CMFPJ reduced growth of EAC cells by 19.53, 49.2, and 68.9% at 25, 50, and 100 mg/kg CMFPJ respectively.

Real time-PCR
-------------

Molecular investigation demonstrated significant alteration in the expression of apoptosis regulatory genes caspase-8, cytochrome-c, caspase-9, and caspase- 3 in EAC grown in all CMFPJ treated groups ([Fig. 4](#f4-tr-35-271){ref-type="fig"}). The expression of the genes was in rising trend with the increasing amount of CMFPJ. CMFPJ increased the expression of caspase-8 in a dose-dependent manner by 1.42, 1.79, and 2.58 fold with 25, 50, and 100 mg/kg, respectively ([Fig. 4](#f4-tr-35-271){ref-type="fig"}). As shown in [Fig. 4](#f4-tr-35-271){ref-type="fig"}, at 25, 50, and 100 mg/kg dose of CMFPJ increased expression of cytochrome- c by 1.29, 1.90, and 2.49 fold respectively. The expression of caspase-9 was amplified by 1.45, 1.83, and 2.87 fold at 25, 50, and 100 mg/kg CMFPJ respectively ([Fig. 4](#f4-tr-35-271){ref-type="fig"}). And the expression of caspase-3 was increased by 1.77, 2.63, and 4.21 fold at 25, 50, and 100 mg/kg CMFPJ respectively ([Fig. 4](#f4-tr-35-271){ref-type="fig"}).

DISCUSSION
==========

Nowadays, phytochemicals are of greater interest in alternative cancer therapy from the points of less toxicity and cost benefit. The CMFPJ contained elevated amount of lectin, flavonoids, and polyphenols. However, in this study, we showed *in vitro* and *in vivo* cytotoxic activity of the CMFPJ in dose-dependent manner.

Lectins are ubiquitous protein with similar biochemical properties performing different functions and are profusely found in seeds and fruits pulp. Lectin was attached to the carbohydrate moieties on the surface of mouse erythrocytes and agglutinated them ([@b19-tr-35-271]). The affinity of lectins towards cancer cell is higher than that of healthy cells ([@b20-tr-35-271]). Thereafter, lectin exhibited EAC growth inhibition by altering cell cycle, inducing non-apoptotic G1-phase accumulation mechanisms, G2/M phase cell cycle arrest, and apoptosis ([@b21-tr-35-271]). According to a previous study, lectin from *Pisum sativum* seed reduced the EAC cell growth by 44 and 63% at 1.4 mg/kg/day and 2.8 mg/kg/day respectively ([@b22-tr-35-271]).

Moreover, plants rich in polyphenols are known to be linked to decrease risk of developing cancer through various mechanisms, including apoptosis ([@b23-tr-35-271]). The phenolic compound of CMFPJ induced oxidative stress on EAC, leading to cell cycle arrest and apoptosis ([@b22-tr-35-271]). Besides, the flavonoids compacted cellular viability through activation of caspase mediated pathways ([@b24-tr-35-271]). A similar study reported that fraction of *Morus alba* rich in polyphenols and flavonoids showed anti-proliferation of EAC by 70.20% at 100 mg/kg/day ([@b17-tr-35-271]). In our case, we found EAC growth inhibition by 19.53, 49.2, and 68.9% at 25, 50, and 100 mg/kg CMFPJ respectively.

We found increased expression of caspase-8, cytochrome- c, caspase-9, and caspase-3 genes. According to the results of altered gene expression, both of the extrinsic pathway and the intrinsic pathway are the probable pathways through which CMFPJ induced apoptosis in EAC cell. Usually, due to ligand binding to exact receptors, the death-inducing signalling complex (DISC) forms and activates caspase-8 in the extrinsic pathway ([@b25-tr-35-271]). In the intrinsic pathway, mitochondria discharge cytochrome-c which participate in the formation of apoptosome and lead to caspase-9 activation ([@b25-tr-35-271]). The activated caspase-8 either directly cleaves effector caspase or cleaves Bid which finally provoke mitochondria to release cytochrome-c ([@b25-tr-35-271]). Then cytochrome-c participates in apoptosome formation with the accumulation of procaspase-9 and apoptotic protease activating factor 1 (APAF1) to activate caspase-9 ([@b25-tr-35-271]). Subsequently, caspase-8 and caspase-9 induce activation of downstream caspase-3 ([@b25-tr-35-271]), the key effector in apoptosis which acts by constrained proteolysis of the structural proteins, including cytokeratins, PARP, and nuclear protein NuMA, and leads to apoptosis ([@b16-tr-35-271]).

However, the inhibition of EAC growth and alteration of caspase pathways possibly were due to the combinatorial effect of lectin, flavonoids, and polyphenols of CMFPJ.
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![Effect of CMFPJ on EAC growth *in vitro*. CMFPJ slowed down EAC cell growth in a dose-dependent manner. The results are represented as mean ± SD (n = 3).](tr-35-271f1){#f1-tr-35-271}

![Hemagglutination activity of CMFPJ. CMFPJ showed hemagglutination activity on mouse RBCs (upper row) but the control wells did not show hemagglutination at any concentration of PBS (lower row).](tr-35-271f2){#f2-tr-35-271}

![*In vivo* effect of CMFPJ on EAC growth inhibition. CMFPJ significantly reduced EAC growth compared to control. Significance levels were determined and set at \**p*\< 0.05, \*\**p*\< 0.01, and \*\*\**p*\< 0.001 in respect to the control. The results are represented as mean ± SD (n = 6).](tr-35-271f3){#f3-tr-35-271}

![Effect of CMFPJ on expression of apoptotic markers (A) caspase-8, (B) cytochrome-c, (C) caspase-9, and (D) caspase-3 in EAC. CMFPJ significantly increased the expression of caspase-8, cytochrome-c, caspase-9, and caspase-3 compared to control. Significance levels were determined and set at \**p*\< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001. The results are represented as mean ± SD (n = 3).](tr-35-271f4){#f4-tr-35-271}
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Primers used for PCR amplification

  Gene           Primer                         Sequence
  -------------- ------------------------------ --------------------------------
  GAPDH          Forward                        5′-GTGGAAGGACTCATGACCACAG-3′
  Reverse        5′-CTGGTGCTCAGTGTAGCCCAG-3′    
  Caspase-8      Forward                        5′-CTGCTGGGGATGGCCACTGTG-3′
  Reverse        5′-TCGCCTCGAGGACATCGCTCTC-3′   
  Cytochrome-c   Forward                        5′-CCAGGTATACAAGCAGGTGTGCTC-3′
  Reverse        5′-CATCATTAGGGCCATCCTGGAC-3′   
  Caspase-9      Forward                        5′-ATGGACGAAGCGGATCGG-3′
  Reverse        5′-CCCTGGCCTTATGATGTT-3′       
  Caspase-3      Forward                        5′-GCAGCAAACCTCAGGGAAAC-3′
  Reverse        5′-GGTTTCCCTGAGGTTTGCTG-3′     
